Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Michael U, Callaghan"'
Publikováno v:
eJHaem, Vol 3, Iss 3, Pp 653-659 (2022)
Abstract Evidence suggests neuropathic pain (NP) develops over time in sickle cell disease (SCD), contributing to a complex, difficult‐to‐treat phenotype, with management based on scant evidence. One characteristic of NP found is hyperalgesia cau
Externí odkaz:
https://doaj.org/article/79f3d00a0a9546438d402decc75279a7
Autor:
Michael U. Callaghan, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse‐Jarres, Víctor Jiménez‐Yuste, Midori Shima, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Flora Peyvandi
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 6, Pp n/a-n/a (2022)
Abstract Background Bleeding in people with hemophilia A can be life threatening, and intra‐articular bleeds can result in joint damage. Most clinical studies focus on treated bleeds, while bleeds not treated with coagulation factor(s) (untreated b
Externí odkaz:
https://doaj.org/article/e0003f2e961e49a1b507a404d3f16f57
Publikováno v:
Expert Opinion on Investigational Drugs. 31:1169-1186
Hemophilia A is a severe bleeding disorder affecting about 1 in 5,000 males. The gold standard for prophylaxis and treatment of acute bleeding has been factor (F) VIII concentrate. A multitude of treatment modalities are now available and under clini
Autor:
Ahmed A. Daak, Carlton D. Dampier, Beng Fuh, Julie Kanter, Ofelia A. Alvarez, L. Vandy Black, Melissa A. McNaull, Michael U. Callaghan, Alex George, Lynne Neumayr, Lee M. Hilliard, Fredrick Sancilio, Adrian L. Rabinowicz, Matthew M. Heeney
Publikováno v:
Blood Advances, Vol 2, Iss 15, Pp 1969-1979 (2018)
Abstract: Blood cell membranes in sickle cell disease (SCD) have low docosahexaenoic acid (DHA). DHA treatment reduces sickle cell crisis (SCC) rate and ameliorates the inflammation, oxidative stress, and hypercoagulable state of SCD. SC411 is a nove
Externí odkaz:
https://doaj.org/article/c9a2061b19044073b673652efda96f67
Publikováno v:
Pediatric Health, Medicine and Therapeutics. 13:27-35
Hemophilia A is the most common severe inherited bleeding disorder in males. Initial treatment strategies focused on the use of factor concentrates to prevent joint bleeding and the development of long-term crippling arthropathy. The current standard
Autor:
Ahmar U. Zaidi, Michael Tarasev, Xiufeng Gao, Ke Liu, Jennell White, Patrick C. Hines, Michael U. Callaghan
Publikováno v:
British Journal of Haematology. 196:1052-1058
Sickle cell disease (SCD) is characterized by frequent and unpredictable vaso-occlusive crises (VOCs). Sickle erythrocytes (SSRBCs) contribute to VOCs by participating in a series of adhesive events with blood cells and the vascular endothelium. Adhe
Autor:
Guy Young, Doris Quon, Janna M. Journeycake, Ismail Haroon Mitha, Thomas A. Wilkinson, Ahmad Al-Sabbagh, Johnny Mahlangu, Alok Srivastava, Philippe de Moerloose, Giancarlo Castaman, Craig M. Kessler, Kateryna V. Vilchevska, Michael Recht, Cédric Hermans, W. Allan Alexander, Michael U. Callaghan, J.-F. Schved, Santiago Bonanad Boix, James V. Luck, Oleksandra Stasyshyn, Wolfgang Miesbach, Robert F. Sidonio, Michael Wang, Amy D. Shapiro, Miguel A. Escobar, Claude Negrier, Jonathan M. Ducore, Christopher Macie, Daniel Bonzo, Cindy A. Leissinger
Publikováno v:
HAEMOPHILIA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Haemophilia, Vol. 27, no. 6, p. 921-931 (2021)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Haemophilia, Vol. 27, no. 6, p. 921-931 (2021)
Introduction Haemophilia patients with inhibitors often require a bypassing agent (BPA) for bleeding episode management. Eptacog beta (EB) is a new FDA-approved recombinant activated human factor VII BPA for the treatment and control of bleeding in h
Autor:
Xiufeng Gao, Ahmar U. Zaidi, Michael U. Callaghan, Patrick C. Hines, Jennell White, Ke Liu, Michael Tarasev
Publikováno v:
British Journal of Haematology. 194:1074-1082
Blood cell adhesion to P-selectin and vascular cell adhesion molecule-1 (VCAM-1) contributes to the pathophysiology of vaso-occlusion crisis (VOC) events in individuals with sickle cell disease (SCD). We evaluated the use of standardized flow adhesio
Autor:
Monica L. Hulbert, Deepa Manwani, Emily Riehm Meier, Ofelia A. Alvarez, R. Clark Brown, Michael U. Callaghan, Andrew D. Campbell, Thomas D. Coates, Melissa J. Frei‐Jones, Jane S. Hankins, Matthew M. Heeney, Lewis L. Hsu, Jeffrey D. Lebensburger, Charles T. Quinn, Nirmish Shah, Kim Smith‐Whitley, Courtney Thornburg, Julie Kanter
Publikováno v:
Pediatric bloodcancerREFERENCES. 70(1)
Sickle cell disease (SCD) requires coordinated, specialized medical care for optimal outcomes. There are no United States (US) guidelines that define a pediatric comprehensive SCD program. We report a modified Delphi consensus-seeking process to dete
Autor:
Amy D. Shapiro, Sylvia von Mackensen, Michael U. Callaghan, Ido Paz-Priel, Midori Shima, Steven W. Pipe, Víctor Jiménez-Yuste, Claude Negrier, Gallia G. Levy, Markus Niggli, Johnny Mahlangu, Sammy Chebon, Avrita Campinha-Bacote, Mark W. Skinner, Michaela Lehle, Johannes Oldenburg
Publikováno v:
Haemophilia
Introduction Severe haemophilia A (HA) has a major impact on health‐related quality of life (HRQoL). Aim Assess the impact of emicizumab on HRQoL in persons with severe HA (PwHA) without factor VIII (FVIII) inhibitors in the phase 3 HAVEN 3 and 4 s